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markers for human gliomas
Cong Hua1†, Gang Zhao1†, Yunqian Li1† and Li Bie1,2*Abstract
Background: Gliomas are the most common type of all central nervous system tumors. Almost all patients
diagnosed with these tumors have a poor prognostic outcome. We aimed to identify novel glioma
prognosis-associated candidate genes.
Methods: We applied WebArrayDB software to span platform integrate and analyze the microarray datasets. We
focused on a subset of the significantly up-regulated genes, the minichromosome maintenance (MCM) family. We
used frozen glioma samples to predict the relationship between the expression of MCMs and patients outcome by
qPCR and western blot.
Results: We found that MCMs expression was significantly up-regulated in glioma samples. MCM2-7 and MCM10
expressions were associated with WHO tumor grade. High MCM2 mRNA expression appeared to be strongly
associated with poor overall survival in patients with high grade glioma. Furthermore, we report that MCM7 is
strongly correlated with patient outcome in patients with WHO grade II-IV tumor. MCM3 expression was found to
be up-regulated in glioma and correlated with overall survival in patients with WHO grade III tumor. MCM2, MCM3
and MCM7 expression levels were of greater prognostic relevance than histological diagnosis according to the
current WHO classification system.
Conclusions: High expression of MCM 2, MCM3 and MCM7 mRNA correlated with poor outcome and may be
clinically useful molecular prognostic markers in glioma.
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Gliomas are one of the most common malignant tumors
of the central nervous system. Gliomas represent a
group of low grade and high grade brain tumors that
originate from glial cells. Most are characterized by
diffuse infiltrative growth in the surrounding brain.
According to the 2007 WHO grading system [1], these
tumors are classified as typical WHO grade I-IV. The
median survival for patients with anaplastic astrocy-
toma (WHO grade III) and glioblastoma (WHO grade
IV) is less than threes years and less than one year,* Correspondence: bieli@aliyun.com
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unless otherwise stated.respectively [2]. The prognosis remains poor despite
extensive research and advances in radiation therapy
and chemotherapeutic regimes [3]. All types of cancer
as well as glioma constitute a major public health
problem that presents several challenges to researchers
such as identification of biomarkers for improved and
early diagnosis, classification of tumors, and the defin-
ition of targets for more effective treatment. Genetic
analysis over the past 30 years has defined the major
mutational targets in the human genome that are asso-
ciated with the formation of glioma [4]. Moreover,
large-scale association genome-wide surveys have been
used to identify new biomarkers that have been developed
as diagnostic and prognostic tools.
In this study, to unravel molecular glioma tumorigenesis
and discover novel molecular biomarkers for diagnostic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ware (www.WebArrayDB.org) to span platform integrate
and analyze the microarray datasets [5-7], including data
stored at the Cancer Genome Anatomy Project (http://
cgap.nci.nih.gov/Genes).
Among the genes up-regulated in gliomas, we focused
on a subset of the significantly up-regulated genes,
the minichromosome maintenance (MCM) family. The
MCM family includes eight members: MCM2-MCM7
and MCM10 [8]. They are considered to function as li-
censing components for the S-phase of cell cycle [9].
MCMs can be expressed in abundance in different cell
cycles and degraded in quiescence, senescence and
differentiation steps thus they can be used as specific
markers of the cell cycle state in tissues [10]. This fea-
ture of MCM genes in proliferating cells has led to
their potential clinical application as a marker for cancer
screening [11].
Here we report that MCM family genes are almost up-
regulated in 59 human glioma tumor samples compared
to six normal brain controls by qRT-PCR. Our study
indicates for the first time that high MCM2 mRNA ex-
pression appears to be strongly associated with poor
overall survival in high grade glioma. Furthermore, we
report that MCM7 is strongly correlated with patient
outcome in WHO grade II-IV. MCM3 expression
found to be up-regulated in glioma and correlated with
overall survival in WHO grade III. MCM2, MCM3 and
MCM7 expression level were of greater prognostic
relevance than histological diagnosis according to the
current WHO classification system. Interestingly, in
the last few years, studies have pointed out the roles of
MCM family members as diagnostic and prognostic
markers for several malignancies [12].
Methods
Patients and tumor samples
A total of 59 glioma specimens were obtained from the
Department of Neurosurgery, First Affiliated Hospital
of Jilin University, from 2003 to 2012. The samples in-
cluded 21 females and 38 males and an age range 2–69
years. Samples were collected immediately after surgi-
cal resection, snap frozen, and stored at −80°C until
used for RNA extraction. All gliomas were samples of
primary tumor before therapy. All cases had been diag-
nosed at the primary hospital by neuropathologists.
Original pathology slides were obtained and reviewed
blinded to the original diagnosis according to the 2007
WHO classification (14 II grade, 21 III grade and 24 IV
grade). The samples consisted of astrocytoma (n = 27),
anaplastic astrocytoma (n = 9) and glioblastoma (n = 23).
Six control samples (normal brain) were obtained from
the Department of Neurosurgery, First Affiliated Hospital
of Jilin University from patients undergoing surgery forbrain trauma (n = 4) and epilepsy (n = 2). They were all
reviewed to verify the absence of tumor. Written
informed consent for participation in the study was
obtained from all participants or their guardians.
The study was approved by the Institutional Review
Board (IRB) of The First Hospital of Jilin University
(IRB00008484).
RNA isolation and quality evaluation
Total RNA was extracted from frozen sections with the
TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) following
the manufacturer’s protocol. Total RNA yield was mea-
sured with an A260/280 ratio of 1.7-1.9, demonstrating
purity. Quality was evaluated on nanochips with the Bio-
Rad Experion automated electrophoresis system (Bio-Rad
Laboratories, Hercules, CA, USA). Samples had a 28S/18S
ratio of 1.5 and did not show evidence of ribosomal peak
degradation.
Real-time quantitative reverse transcription PCR
About 500 ng total RNA from each sample was reverse
transcribed with SuperScript II Reverse Transcriptase
(Invitrogen, Carlsbad, CA, USA). Primers were designed
with AlleleID Version 7.0 software (Premierbiosoft, Palo
Alto, CA, USA). Predesigned gene expression assays
were obtained from Integrated Device Technology
(IDT, San Diego, CA, USA). Real-time quantitative PCR
was then carried out using an ABI Prism 7900 Sequence
Detection System (Applied Biosystems, Carlsbad, CA,
USA). A quantity of 15 ng of cDNA was used in a 25 μl
PCR reaction containing the appropriate primers and
1 × SYBR Green PCR Super mix (BioPioneer, San Diego,
CA, USA). All products were 77 to 134 bp. Dissociation
curves of each sample were used to check the specificity
of amplification. PCR reactions were examined by 1.6%
agarose gel electrophoresis for verification of dissoci-
ation curve results. Parallel experiments were carried
out using an 18S rRNA and HPRT1 primer set. qPCR
reactions were performed in triplicate, and the relative
fold changes were calculated with the Pfaffl method [13]
for each gene corrected using 18S rRNA +HPRT1[14].
All primer pairs utilized in this study presented amplifi-
cation efficiency between 91-110% (Additional file 1).
Western blot
To detect MCM2, MCM3 and MCM7 protein in glioma
tumors, we examined six glioma samples (two each of
WHO stages II, III, IV). The protein concentration of
cell lysates was determined by the Bio-Rad Protein Assay
(Bio-Rad Laboratories, Hercules, CA, USA) according to
the manufacturer’s instructions. Thirty micrograms of
protein per tissue lysate was electrophoresed on 7-12%
gels and transferred to a polyvinylidene difluoride mem-
brane filter (Millipore, Billerica, MA, USA). Blots were
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termination of the protein was assessed by densitometric
scanning of the band from film. An AlphaImager 2000
Documentation and Analysis System (Alpha Innotech
Corp, San Leandro, CA, USA) was used to quantify bands
of appropriate sizes.
The following primary antibodies were used: anti-
β-actin (Sigma Chemical Co, St. Louis MO, USA),
anti-MCM2 (sc-10771, Santa Cruz Biotechnology, USA),
anti-MCM3 (sc-9849, Santa Cruz Biotechnology, USA),
and anti-MCM7 (sc-22782, Santa Cruz Biotechnology,
USA).
Statistical analysis
The statistical significance of differences in the means
was calculated using the ANVOA test. To identify a
model describing the relationship between survival and
the MCMs mRNA expression, the functional form of the
relationship was tested by maximally selected log-rank
statistics as previously described [15]. The resulting model
was applied in further survival analyses. Multivariate Cox
regression was used to investigate the prognostic power of
candidate gene expression adjusting for established prog-
nostic variables. The Cox proportional hazards regression
were carried out with the use of the design and survival
package of the R software environment. Overall survival
curves (from diagnosis to death) were obtained using the
Kaplan-Meier method and compared with a log-rank test.
A p value of less than 0.05 was considered to indicate
statistical significance.
Results
Up-regulation of the MCM family expression in human
glioma samples
The mRNA expression level of the MCM family mem-
bers were examined in 59 human glioma samples and
six normal brain tissues by qPCR (n = 3), normalized to
18S rRNA and HPRT1 levels. We found a significant
increase in MCM2 (3.5 fold), MCM3 (3.1 fold), MCM4
(4.3 fold), MCM5 (3.8 fold), MCM6 (3.5 fold), MCM7
(3.0 fold) and MCM10 (3.6 fold) expressions in tumor
tissues (the average fold value of three grades) compared
to the normal brain controls. Moreover, as shown in
Table 1, we observed that MCM3-MCM5,MCM7 and
MCM10 were significantly changed between grade II, III
and IV samples (p < 0.05). MCM2 and MCM6 were
significantly increased between grade II (low grade) and
III-IV (high grade) samples (p < 0.05). Four independent
external microarray datasets (8 normal, 29 stage II, 116
stage III and 618 stage IV, Additional file 2) were ana-
lyzed using the WebArrayDB cross-platform analysis
suite to validate our experiment results. Genes were
sorted in ascending order according to the p values for
WHO grade, after taking into account gender andpatient age as variables. Expression of MCM family
members was highly correlated with glioma grade
(Table 1). To confirm the specificity of the qPCR re-
sults, we characterized MCM2, MCM3, MCM7, as well
as β-actin as a loading control, in six glioma samples
for which freshly frozen materials were available. As
shown in Figure 1, an immunoreactive band of MCM2,
MCM3 and MCM7 were seen in all six cases of gliomas,
MCM2, MCM3 and MCM7 expressions were significantly
higher in malignant tissues than in tissues with low malig-
nant potential.
Multivariate survival analysis of prognostic parameters
Multivariate survival analysis identified high expression
of MCM2 as an independent prognostic factor for sur-
vival time, as well as MCM3 and MCM7 (p < 0.05),
(Table 2).
The MCMs expression correlates with poor outcome in
patients with glioma
We reviewed each grade of tumor separately and investi-
gated whether the expression of MCM2, MCM3 and
MCM7 predicts patient survival within each subgroup.
The search for a model describing the relationship be-
tween survival and expression of MCM family genes
expression using maximally selected log-rank statistics
identified a cutoff model to be most suitable: MCM2
(fold change cutoff for stage II 2.3, III 4.7, and IV 5.6,),
MCM3(II 2.4, III 3.1, and IV 5.3) and MCM7 (II 1.6, III
4.6, and IV 6.1). The qPCR cutoff ratios were used to
separate two patient subgroups with significantly dif-
ferent outcomes [maximally selected log rank statis-
tics, p < 0.05 (overall survival)]. Applying these MCM
family expression cutoff to Kaplan-Meier survival
curve estimation revealed decreased survival probabil-
ity for patients with tumor expressing high levels of
MCM2, MCM3 and MCM7 (p < 0.05), (Figure 2). In
the grade II group, MCM7 expression appeared to be a
strongly positive prognostic factor (p < 0.01). In the
grade III group, better prognosis was found for pa-
tients with glioma with low expression of three genes
compared to patients with high expression (p < 0.01).
MCM2 and MCM7 expression appeared to be prog-
nostic factors in the grade IV group, although they are
not strongly positive in any of these cases (p < 0.05).
Thus the expression level of MCM2, MCM3 and
MCM7 reveal information on the survival probability
for patients with glioma beyond that revealed by grade
alone.
The result was validated by GBM database. Repository
of Molecular Brain Neoplasia Data (Rembrandt, https://
caintegrator.nci.nih.gov/rembrandt/), a cancer clinical gen-
omics database and a Web-based data mining and analysis
platform aimed at facilitating discovery by connecting
Table 1 Comparison of mRNA expression of MCMs in glioma tumor tissue by qRT-PCR and microarray analysis
Gene Unique ID Gene origin Fold p value
II/Normal III/Normal IV/Normal III/II IV/II IV/III (II-IV)/Normal II→Normal III→Normal IV→Normal III→ II IV→ II IV→ III
MCM2 202107_s_at qRT-PCR 1.91 3.9 4.22 2.04 2.21 1.08 3.5 1.27E-02 1.38E-04 5.43E-10 1.20E-04 4.91E-10 3.84E-01
Microarray 1.61 3.68 5.39 2.16 3.16 1.47 2.84E-02 5.22E-05 8.61E-09 5.33E-09 0.00E + 00 1.53E-05
MCM3 201555_at qRT-PCR 1.59 3.01 4.46 1.89 2.81 1.49 3.1 1.08E-01 2.51E-02 8.25E-10 2.00E-02 1.46E-11 3.86E-03
Microarray 1.92 2.32 2.79 1.26 1.52 1.2 1.57E-02 1.14E-04 2.45E-07 3.24E-02 1.18E-07 3.26E-03
MCM4 222036_s_at qRT-PCR 2.41 4.56 6.15 1.89 2.55 1.35 4.3 1.14E-03 2.42E-04 2.11E-06 6.07E-04 2.33E-07 2.81E-02
Microarray 0.81 1.51 1.61 1.58 1.69 1.07 1.00E + 00 5.07E-01 2.01E-01 9.64E-06 6.36E-09 7.04E-01
MCM5 201755_at qRT-PCR 1.91 4.25 4.48 2.22 2.34 1.05 3.8 1.49E-02 2.38E-04 5.92E-07 3.32E-05 1.49E-02 1.43E-02
Microarray 0.57 1.95 2.46 2.03 2.57 1.26 7.88E-01 5.97E-01 1.14E-01 1.19E-04 7.13E-10 1.23E-01
MCM6 201930_at qRT-PCR 1.28 4.8 4.63 3.76 3.62 0.96 3.5 4.46E-01 4.46E-05 8.26E-09 2.65E-07 6.85E-12 7.04E-01
Microarray 2.24 2.63 3.05 2.07 2.4 1.16 2.82E-03 1.83E-02 3.22E-02 4.30E-13 0.00E + 00 7.39E-02
MCM7 208795_s_at qRT-PCR 1.51 3.29 4.33 2.17 2.86 1.32 3.0 3.39E-01 1.82E-02 1.34E-08 1.25E-02 5.59E-09 4.95E-02
Microarray 1.02 2.23 2.08 1.79 1.67 0.93 1.00E + 00 8.94E-04 1.93E-03 5.57E-10 6.93E-10 6.36E-01
MCM10 220651_s_at qRT-PCR 2.58 3.86 4.73 1.5 1.83 1.22 3.6 5.72E-05 3.31E-04 3.20E-08 8.96E-03 4.41E-07 6.48E-02
Microarray 6.18 26.21 31.81 3.54 4.29 1.21 1.46E-02 6.54E-09 3.05E-10 4.62E-07 1.77E-11 5.83E-01
MCM3 and MCM5,MCM7 and MCM10 were significant different between grade II, III and IV samples (p < 0.05). MCM2 and MCM6 expressions were significantly increased between grade II (low grade) and III-IV (high grade)


















Figure 1 Expression of MCM2, MCM3 and MCM7 protein in
gliomas by Western blot. A western blots of six glioma samples
(WHO grade II, III and IV). B Quantitation of the western blots by
using β-actin as the loading control.
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characterization data. The microarray data are available
for 181 GBM samples in Rembrandt database. MCM2 and
MCM3 were not correlate with the prognosis of GBM
patients (p > 0.05). When the cut-off point was the up-
regulation of 2 fold, MCM7 was significant relative to
the outcome of GBM patients (p < 0.01), (Table 3).
Discussion
Glioma tumors are the most common and deadly brain
tumors. However, the survival of patients with low gradeTable 2 Multivariate analysis on prognosis of the patients
(n = 59)
Parameter Risk ratio 95% CI p
Sex 2.067 0.789-4.670 0.151
Age (≥40) 3.155 1.984-4.039 0.042
WHO (Grade 4) 3.0843 1.523-3.810 0.034
MCM2 8.519 6.280-10.508 0.004
MCM3 7.328 5.102-9.833 0.007
MCM4 0.506 0.843-1.441 0.477
MCM5 2.117 0.946-3.127 0.146
MCM6 2.873 1.377-4.073 0.090
MCM7 6.576 4.114-8.243 0.010
MCM10 0.029 0.015-1.093 0.937(stage II) glioma is significantly higher than that of pa-
tients with high grade (stage III-IV) tumors. In the study,
we applied WebArrayDB software (www.WebArrayDB.
org) to analysis three independent microarray datasets
which come from different microarray platforms. We
focused on the part of the members of the MCM gene
family most highly significantly up-regulated in gliomas.
MCMs were first discovered in the mutants of the
yeast Saccharomyces cerevisiae that had defects in main-
taining a simple minichromosome [16]. MCM 2–7 form
a heterohexamer complex [17]. The MCM protein com-
plex is associated with the origins of DNA replication to
form part of the pre-replicative complex. Activation of
MCM complex by cyclin-dependent kinases, such as
Cdc6, Cdt1 andDbf4/Cdc7, leads to initiation of DNA
synthesis [18]. The hexameric MCM component of the
pre-replicative complex exhibits helicase activity that
may make DNA unwind during replication [11]. Thus,
MCM proteins allow the DNA replication machinery to
access binding sites on DNA [19]. Several studies sug-
gested that increased levels of MCMs can identify not
only malignant cells [20-25] but also precancerous cells
and tumor recurrence [26-28], indicating that they might
also serve as prognostic tumor markers. The last member,
MCM10, may have a dual function: firstly to stabilize
DNA polymerase-α-primase and secondly to target it to
chromatin [29].
Recent studies have proven that MCMs expression has
a relationship with diagnosis and prognosis. MCM2 and
MCM3 seem to have the most important role in several
types of neoplasia, including alimentary system tumors
[30-35], genitourinary system tumors [36-41], lung can-
cer [42,43], breast cancer [44-47], and meningioma
[27,48]. Moreover, several investigators have found that
the measurement of MCM6 protein expression is a
good diagnostic marker for chondrosarcoma [49], and
lymphoma [50]. MCM2, MCM3 and MCM7 proteins
expression is also known to be an important tool for
estimating tumor proliferation and a useful adjunct to
the routinely used proliferation markers for glioma
diagnosis [51-56].
Moreover, in past research, MCMs have also provided
useful information on outcome of patients with glioma.
Wharton et al. found that cases with a high MCM2
labeling index had a poorer prognosis than those with a
low index in patients with oligodendroglioma [51]. Scott
et al. reported that the cyclin A:MCM2 labeling fraction
might predict a relatively favorable response to radical
radiotherapy in patients with glioblastoma [52]. Söling
et al. in their series of patients with astrocytoma found
that high MCM3 expression is an independent predictor
of poor outcome [53].
Compared with previous reports, we confirmed MCM
2, MCM 3 and MCM7 expression were correlated with
Figure 2 Kaplan-Meier estimates of overall survival (OS) in relation to MCM2, MCM3 and MCM7 expression as determined by qPCR.
Cutoff value for dichotomization of MCM2, MCM3 and MCM7 expression and p values were determined by maximally selected log-rank statistics.
A High MCM2 expression appeared to be strongly associated with poor overall survival in high grade glioma. B MCM3 expression was to be
up-regulated in glioma and correlated with OS in the grade III group, In the grade III group, the expression of three genes was significantly
associated with patient outcome (p < 0.01); C MCM7 expression appeared to be a strongly positive prognostic factor in the WHO grade II-IV
group (p < 0.01).
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by microarray data analysis and qPCR. The result of
western blot also validated this finding. Some studies
reported positive correlations in the expression of
MCMs with Ki67 [44,47,57]. Moreover, several stud-
ies have revealed that MCMs are characterized by
higher specificity and sensitivity than other conven-
tional proliferative markers [58,59]. Ki-67 is a crucial
molecular marker for estimating the progression and
prognosis of gliomas [60,61]. Despite the fact that
MCMs and Ki67 have a similar expression pattern
during many cell cycle phases (G1, S, G2 and M
phases), detailed cell-cycle analysis shows differences
between both markers. Ki67 is absent during the early
G1 phase, whereas MCMs are expressed in the entire
G1 phase. As such, the degree of tumor cell prolifera-
tion may be better reflected by using MCMs.
Kaplan-Meier analysis showed that MCM2, MCM3
and MCM7 can function as an independent prognostic
indicator for overall survival (p < 0.05). Our study indi-
cates for the first time that high MCM2 mRNA expres-
sion appears to be strongly associated with poor overall
survival in high grade glioma. MCM3 expression wasTable 3 Comparison of mRNA expression of MCM2, MCM3 an
(Rembrandt, https://caintegrator.nci.nih.gov/rembrandt/)
Gene Unique ID Gene origin Number o
Group 1
MCM2 202107_s_at Microarray 133
MCM3 201555_at Microarray 138
MCM7 208795_s_at Microarray 59
p < 0.05.
MCM2 and MCM3 were not correlate with the prognosis of GBM patients (p > 0.05).
correlate with the outcome of GBM patients (p < 0.01).found to be up-regulated in glioma and correlated with
overall survival in the grade III group. However, MCM3
does not appear to be a predictor of survival in the
patients of the grade IV group. Söling et al. have also re-
ported results supporting this conclusion [53]. Likewise,
MCM2 and MCM3 expression in grade II group does
not appear to be a significant predictor, although this
might be explained by the limited sample size. Further-
more, we report that MCM7 is correlated with patient
outcome in grade II-IV group. Erkan EP et al. also report
MCM7 was the significant up-regulate gene in GBM
samples compared with normal white matter tissues.
Moreover, siRNA-mediated knockdown of MCM7 expres-
sion reduced GBM cell proliferation and also inhibited
tumor growth in both xenograte and orthotopic mouse
models of GBM [56].
Conclusions
In conclusion, the results suggest that MCM2, MCM3
and MCM7 play important roles in glioma tumor progres-
sion. Most notably, MCM2, MCM3 and MCM7 aberra-
tions in glioma tumors portend a particularly aggressive
clinical behavior.d MCM7 in glioma tumor tissue by microarray analysis
f samples (all upregulate) Fold p value




When the cutoff point was the up-regulation of 3fold, MCM7 was significant
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